7443-72-3 Usage
Uses
Used in Pharmaceutical Industry:
13-Ethyl-3-methoxygona-1,3,5(10),8-tetraen-17beta-ol is used as a reactant in the synthesis of new immunogens for levonorgestrel, a synthetic progestin hormone. Levonorgestrel is widely used in contraceptives, hormone replacement therapy, and treatment of certain gynecological conditions. 13-Ethyl-3-methoxygona-1,3,5(10),8-tetraen-17beta-ol is also used in the synthesis of its 3-syn and anti-oximes, which are important intermediates in the development of novel pharmaceutical agents with potential applications in various therapeutic areas.
In the synthesis of new immunogens, 13-Ethyl-3-methoxygona-1,3,5(10),8-tetraen-17beta-ol serves as a key building block, providing the necessary structural features required for the development of immunogenic compounds. These immunogens can be used to stimulate the immune system to produce a specific immune response, which can be beneficial in the treatment of various diseases and conditions.
Furthermore, the compound's unique structural properties make it a valuable asset in the development of new drugs with improved efficacy, safety, and pharmacokinetic profiles. By incorporating 13-Ethyl-3-methoxygona-1,3,5(10),8-tetraen-17beta-ol into the synthesis process, researchers can potentially create novel pharmaceutical agents with enhanced therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 7443-72-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,4,4 and 3 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 7443-72:
(6*7)+(5*4)+(4*4)+(3*3)+(2*7)+(1*2)=103
103 % 10 = 3
So 7443-72-3 is a valid CAS Registry Number.
InChI:InChI=1/C20H26O2/c1-3-20-11-10-16-15-7-5-14(22-2)12-13(15)4-6-17(16)18(20)8-9-19(20)21/h5,7,12,18-19,21H,3-4,6,8-11H2,1-2H3/t18-,19-,20-/m0/s1
7443-72-3Relevant academic research and scientific papers
Total synthesis with a chirogenic opening move demonstrated on steroids with estrane or 18a-homoestrane skeleton
Quinkert,Del Grosso,Doring,Doring,Schenkel,Bauch,Dambacher,Bats,Zimmermann,Durner
, p. 1345 - 1391 (2007/10/02)
A concept of first choice for the synthesis of the title compounds had been proposed by Dane in the late 1930s. It was soon turned down, because the opening move - a chirogenic Diels-Alder reaction - did not work. With Lewis acids as mediators, however, a successful start has been achieved now. With Ti complexes of chelating ligands (Seebach's TADDOLs (= α,α,α',α'-tetraaryl-1,3-dioxolane-4,5-dimethanols)), enantioselective formation of the desired adducts does occur. Efficient total syntheses of 2 and 3a have been accomplished.
